Home The Word Brain | My Amedeo FAQ Privacy About | ||||||||||
The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al. |
Breast Cancer |
Free Subscription
3 Am J Surg |
Retrieve available abstracts of this week’s articles:
HTML format |
Single Articles |
AMEDEO Breast Cancer is free of charge.
Paget's disease of the breast: Presentation, treatment, and outcomes in a modern
cohort.
Am J Surg. 2024;231:18-23.
PubMed
Abstract available
Paget's disease of the breast: Insights from imaging to guide surgical
management.
Am J Surg. 2024;231:16-17.
PubMed
Preoperative depression and anxiety associated with younger age and receipt of
immediate breast reconstruction.
Am J Surg. 2024;231:106-112.
PubMed
Abstract available
TRPS1 is a Highly Sensitive Marker for Breast Cancer: A Tissue Microarray Study
Evaluating More Than 19,000 Tumors From 152 Different Tumor Entities.
Am J Surg Pathol. 2024 Apr 22. doi: 10.1097/PAS.0000000000002213.
PubMed
Abstract available
Antibody-drug conjugates in lung and breast cancer: Current evidence and future
directions - a position statement from the ETOP IBCSG Partners Foundation.
Ann Oncol. 2024 Apr 20:S0923-7534(24)00108-X. doi: 10.1016/j.annonc.2024.
PubMed
Abstract available
The Role of Axillary Lymph Node Dissection versus Sentinel Lymph Node Dissection
in Breast Cancer Patients with Clinical N2b-N3c Disease Who Receive Adjuvant
Radiotherapy.
Ann Surg Oncol. 2024 Apr 22. doi: 10.1245/s10434-024-15280.
PubMed
Abstract available
Systematic optimization and evaluation of culture conditions for the construction
of circulating tumor cell clusters using breast cancer cell lines.
BMC Cancer. 2024;24:507.
PubMed
Abstract available
Real world study of sacituzumab govitecan in metastatic triple-negative breast
cancer in the United Kingdom.
Br J Cancer. 2024 Apr 24. doi: 10.1038/s41416-024-02685.
PubMed
Abstract available
Reply to comment on 'An increase in tumor-infiltrating lymphocytes after
treatment is significantly associated with a poor response to neoadjuvant
endocrine therapy for estrogen receptor-positive/HER2-negative breast cancers' by
Fukui et al.
Breast Cancer. 2024;31:536-538.
PubMed
Global untargeted and individual targeted plasma metabolomics of breast cancer
recurrence modified by hormone receptors.
Breast Cancer. 2024 Apr 23. doi: 10.1007/s12282-024-01579.
PubMed
Abstract available
Perspectives for the clinical application of ctDNA analysis to breast cancer drug
therapy.
Breast Cancer. 2024 Apr 23. doi: 10.1007/s12282-024-01571.
PubMed
Abstract available
Number of lines of previous chemotherapy regimen might affect the oucome of
sacituzumab govitecan in metastatic triple-negative breast cancer patients.
Breast Cancer. 2024 Apr 22. doi: 10.1007/s12282-024-01587.
PubMed
Comparing survival outcomes between neoadjuvant and adjuvant chemotherapy within
T2N1M0 stage hormone receptor-positive, HER2-negative breast cancer: a
retrospective cohort study based on SEER database.
Breast Cancer. 2024 Apr 21. doi: 10.1007/s12282-024-01583.
PubMed
Abstract available
Concordance of HER2 status between core needle biopsy and surgical resection
specimens of breast cancer: an analysis focusing on the HER2-low status.
Breast Cancer. 2024 Apr 21. doi: 10.1007/s12282-024-01585.
PubMed
Abstract available
Real-world progression-free survival and overall survival of palbociclib plus
endocrine therapy (ET) in Japanese patients with hormone receptor-positive/human
epidermal growth factor receptor 2-negative advanced breast cancer in the
first-line or seco
Breast Cancer. 2024 Apr 20. doi: 10.1007/s12282-024-01575.
PubMed
Abstract available
The influence of a previous implant-based breast reconstruction on postoperative
sensation of the deep inferior epigastric artery perforator flap.
Breast Cancer. 2024;31:456-466.
PubMed
Abstract available
Impact of neoadjuvant chemotherapy on the safety and long-term outcomes of
patients undergoing immediate breast reconstruction after mastectomy.
Breast Cancer. 2024;31:507-518.
PubMed
Abstract available
Correlation between postoperative treatment selection and prognosis determined
using the Oncotype DX(R) test data: a retrospective multicenter study in Japan.
Breast Cancer. 2024;31:401-408.
PubMed
Abstract available
Prognosis of primary breast salivary gland-type carcinoma: a propensity
score-matching analysis with invasive carcinoma of no special type based on the
SEER database for years 2010-2020.
Breast Cancer. 2024;31:496-506.
PubMed
Abstract available
Screening mammography performance according to breast density: a comparison
between radiologists versus standalone intelligence detection.
Breast Cancer Res. 2024;26:68.
PubMed
Abstract available
Clustering of HR + /HER2- breast cancer in an Asian cohort is driven by immune
phenotypes.
Breast Cancer Res. 2024;26:67.
PubMed
Abstract available
NSABP FB-10: a phase Ib/II trial evaluating ado-trastuzumab emtansine (T-DM1)
with neratinib in women with metastatic HER2-positive breast cancer.
Breast Cancer Res. 2024;26:69.
PubMed
Abstract available
AMD1 promotes breast cancer aggressiveness via a spermidine-eIF5A
hypusination-TCF4 axis.
Breast Cancer Res. 2024;26:70.
PubMed
Abstract available
Quantitative characterization of breast lesions and normal fibroglandular tissue
using compartmentalized diffusion-weighted model: comparison of intravoxel
incoherent motion and restriction spectrum imaging.
Breast Cancer Res. 2024;26:71.
PubMed
Abstract available
siRNA treatment targeting integrin alpha11 overexpressed via EZH2-driven axis
inhibits drug-resistant breast cancer progression.
Breast Cancer Res. 2024;26:72.
PubMed
Abstract available
A systematic review and meta-analysis of diagnostic performance of
fluorescein-guided sentinel lymph node biopsy in early breast cancer.
Breast Cancer Res Treat. 2024 Apr 26. doi: 10.1007/s10549-024-07310.
PubMed
Abstract available
Perspectives on shorter durations of anti-HER2 therapy in early-stage
HER2-positive breast cancer: a patient survey.
Breast Cancer Res Treat. 2024 Apr 25. doi: 10.1007/s10549-024-07302.
PubMed
Abstract available
Characteristics and risk factors of axillary lymph node metastasis of
microinvasive breast cancer.
Breast Cancer Res Treat. 2024 Apr 25. doi: 10.1007/s10549-024-07305.
PubMed
Abstract available
Impact of HER2 status on clinicopathological characteristics and pathological
complete response to neoadjuvant chemotherapy in triple-negative breast cancer.
Breast Cancer Res Treat. 2024 Apr 24. doi: 10.1007/s10549-024-07317.
PubMed
Abstract available
Randomized trials of estrogen-alone and breast cancer incidence: a meta-analysis.
Breast Cancer Res Treat. 2024 Apr 23. doi: 10.1007/s10549-024-07307.
PubMed
Abstract available
Superior suppression of serum estrogens during neoadjuvant breast cancer
treatment with letrozole compared to exemestane.
Breast Cancer Res Treat. 2024 Apr 23. doi: 10.1007/s10549-024-07313.
PubMed
Abstract available
Racial disparities in outcomes of patients with stage I-III triple-negative
breast cancer after adjuvant chemotherapy: a post-hoc analysis of the E5103
randomized trial.
Breast Cancer Res Treat. 2024 Apr 23. doi: 10.1007/s10549-024-07308.
PubMed
Abstract available
Ethnic disparities in breast cancer patterns in Brazil: examining findings from
population-based registries.
Breast Cancer Res Treat. 2024 Apr 21. doi: 10.1007/s10549-024-07314.
PubMed
Abstract available
Evaluation of markers of immunity in different metastatic immune
microenvironments suggests more suppression within breast to liver metastases in
breast cancer.
Breast Cancer Res Treat. 2024 Apr 20. doi: 10.1007/s10549-024-07295.
PubMed
Abstract available
Cancer Epidemiol Biomarkers Prev
Red Blood Cell Polyunsaturated Fatty Acids and Mortality Following Breast Cancer.
Cancer Epidemiol Biomarkers Prev. 2024.
PubMed
Abstract available
IL1R2 blockade alleviates immunosuppression and potentiates anti-PD-1 efficacy in
triple-negative breast cancer.
Cancer Res. 2024 Apr 24. doi: 10.1158/0008-5472.CAN-23-3429.
PubMed
Abstract available
The Introduction of Magtrace(R) Lymphatic Tracer for Axillary Sentinel Node Biopsy
for Breast Cancer in a Rural Scottish District General Hospital: Initial
Experience, Perspectives, Outcomes and Learning Curves.
Clin Breast Cancer. 2024 Mar 30:S1526-8209(24)00099.
PubMed
Abstract available
Gene-expression assays to tailor adjuvant endocrine therapy for HR+/HER2- breast
cancer.
Clin Cancer Res. 2024 Apr 24. doi: 10.1158/1078-0432.CCR-23-4020.
PubMed
Abstract available
Time trend of breast cancer-related lymphedema according to body mass index.
Eur J Surg Oncol. 2024;50:108350.
PubMed
Abstract available
ESR Essentials: screening for breast cancer - general recommendations by EUSOBI.
Eur Radiol. 2024 Apr 24. doi: 10.1007/s00330-024-10740.
PubMed
Abstract available
Concordance between ER, PR, Ki67, and HER2-low expression in breast cancer by
MammaTyper RT-qPCR and immunohistochemistry: implications for the practising
pathologist.
Histopathology. 2024 Apr 23. doi: 10.1111/his.15193.
PubMed
Abstract available
A dedicated structured data set for reporting of invasive carcinoma of the breast
in the setting of neoadjuvant therapy: recommendations from the International
Collaboration on Cancer Reporting (ICCR).
Histopathology. 2024;84:1111-1129.
PubMed
Abstract available
Blockade of a novel MAP4K4-LATS2-SASH1-YAP1 cascade inhibits tumorigenesis and
metastasis in luminal breast cancer.
J Biol Chem. 2024 Apr 22:107309. doi: 10.1016/j.jbc.2024.107309.
PubMed
Abstract available
Datopotamab Deruxtecan in Advanced or Metastatic HR+/HER2- and Triple-Negative
Breast Cancer: Results From the Phase I TROPION-PanTumor01 Study.
J Clin Oncol. 2024 Apr 23:JCO2301909. doi: 10.1200/JCO.23.01909.
PubMed
Abstract available
Frequent Amplification and Overexpression of PSMA in Basallike Breast Cancer from
Analysis of The Cancer Genome Atlas.
J Nucl Med. 2024 Apr 25:jnumed.123.266659. doi: 10.2967/jnumed.123.266659.
PubMed
Abstract available
Seroma formation after mastectomy: A systematic review and network meta-analysis
of different flap fixation techniques.
J Surg Oncol. 2024;129:1015-1024.
PubMed
Abstract available
Malignant upgrade rate and associated clinicopathologic predictors for concordant
intraductal papilloma without atypia: A systematic review and meta-analysis.
J Surg Oncol. 2024;129:1025-1033.
PubMed
Abstract available
Navigating the complexity of post-NAT therapy in breast cancer: The role of ctDNA
testing.
J Surg Oncol. 2024 Apr 23. doi: 10.1002/jso.27658.
PubMed
US Breast Cancer Mortality.
JAMA. 2024 Apr 25. doi: 10.1001/jama.2024.5479.
PubMed
US Breast Cancer Mortality-Reply.
JAMA. 2024 Apr 25. doi: 10.1001/jama.2024.5482.
PubMed
Upgrade Rates of Variant Lobular Carcinoma In Situ Compared to Classic Lobular
Carcinoma In Situ Diagnosed in Core Needle Biopsies: A 10-Year Single Institution
Retrospective Study.
Mod Pathol. 2024;37:100462.
PubMed
Abstract available
Axillary Dissection - The Bell Tolls for Thee.
N Engl J Med. 2024;390:1231-1232.
PubMed
Peripheral immune cells in metastatic breast cancer patients display a systemic
immunosuppressed signature consistent with chronic inflammation.
NPJ Breast Cancer. 2024;10:30.
PubMed
Abstract available
Kataegis in clinical and molecular subgroups of primary breast cancer.
NPJ Breast Cancer. 2024;10:32.
PubMed
Abstract available
Subgroup analyses from the phase 3 ASCENT study of sacituzumab govitecan in
metastatic triple-negative breast cancer.
NPJ Breast Cancer. 2024;10:33.
PubMed
Abstract available
Decorin suppresses tumor lymphangiogenesis: A mechanism to curtail cancer
progression.
Proc Natl Acad Sci U S A. 2024;121:e2317760121.
PubMed
Abstract available
Very accelerated partial breast irradiation in 1 or 2 days: Late toxicity and
early oncological outcome of the GEC-ESTRO VAPBI cohort.
Radiother Oncol. 2024;194:110217.
PubMed
Abstract available
Skin dose-volume predictors of moderate-severe late side effects after whole
breast radiotherapy.
Radiother Oncol. 2024;194:110183.
PubMed
Abstract available
Thank you for your interest in scientific medicine.